Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost
- Authors
- Kim, Woo Joo; Roberts, Christine C.; Song, Joon Young; Yoon, Jin Gu; Seong, Hye; Hyun, Hak-Jun; Lee, Hyojin; Gil, Areum; Oh, Yeeun; Park, Ji-Eun; Lee, Ji-Eun; Jeon, Bohyun; Kane, Deborah; Spruill, Susan; Kudchodkar, Sagar B.; Muthumani, Kar; Park, Young K.; Kwon, Ijoo; Maslow, Joel N.
- Issue Date
- Jun-2023
- Publisher
- Elsevier BV
- Citation
- Vaccine, v.41, no.29, pp 4206 - 4211
- Pages
- 6
- Indexed
- SCIE
SCOPUS
- Journal Title
- Vaccine
- Volume
- 41
- Number
- 29
- Start Page
- 4206
- End Page
- 4211
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/63778
- DOI
- 10.1016/j.vaccine.2023.06.013
- ISSN
- 0264-410X
1358-8745
- Abstract
- Heterologous boost regimens are being increasingly considered against SARS-CoV-2. We report results for the 32 of 45 participants in the Phase 1 CoV2-001 clinical trial (Kim et al., Int J Iinfect Dis 2023, 128:112- 120) who elected to receive an EUA-approved SARS-CoV-2 mRNA vaccine 6 to 8 months following a two -dose primary vaccination with the GLS-5310 bi-cistronic DNA vaccine given intradermally and followed by application of suction using the GeneDerm device. Receipt of EUA-approved mRNA vaccines after GLS-5310 vaccination was well-tolerated, with no reported adverse events. Immune responses were enhanced such that binding antibody titers, neutralizing antibody titers, and T-cell responses increased 1,187-fold, 110-fold, and 2.9-fold, respectively. This paper is the first description of the immune responses following heterologous vaccination with a DNA primary series and mRNA boost. & COPY; 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Infectious Diseases > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.